Who are amiodarone beta blocker sotalol's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/amiodarone-beta-blocker-sotalol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

amiodarone beta blocker sotalol — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

amiodarone beta blocker sotalol (amiodarone beta blocker sotalol) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-blocker with Class III antiarrhythmic activity. Area: Cardiovascular.

marketed Beta-blocker with Class III antiarrhythmic activity Beta-1 and beta-2 adrenergic receptors; potassium channels (IKr) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

amiodarone beta blocker sotalol (amiodarone beta blocker sotalol) — Connolly, Stuart, M.D.. Sotalol is a non-selective beta-blocker with additional Class III antiarrhythmic activity that slows heart rate and prolongs the cardiac action potential to prevent arrhythmias.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
amiodarone beta blocker sotalol TARGET	amiodarone beta blocker sotalol	Connolly, Stuart, M.D.	marketed	Beta-blocker with Class III antiarrhythmic activity	Beta-1 and beta-2 adrenergic receptors; potassium channels (IKr)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-blocker with Class III antiarrhythmic activity class)

Connolly, Stuart, M.D. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). amiodarone beta blocker sotalol — Competitive Intelligence Brief. https://druglandscape.com/ci/amiodarone-beta-blocker-sotalol. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab